Portola Pharmaceuticals, Inc. announced that an abstract detailing interim results from the company’s ongoing Phase 3b/4 trial of its investigational Factor Xa reversal agent, andexanet alfa, has been accepted for oral presentation during a late-breaking clinical trial session at the American College of Cardiology’s 67th Annual Scientific Session & Expo (ACC.18). The data will be presented on March 12, 2018 at 11:30 a.m. ET. Portola is developing andexanet alfa as a universal antidote for patients anticoagulated with an oral or injectable Factor Xa inhibitor who experience a serious uncontrolled or life-threatening bleeding event or who require urgent or emergency surgery. Andexanet alfa is currently under review by the U.S. Food and Drug Administration (FDA), with an assigned action date of May 4, 2018, and by the European Medicines Agency (EMA), with an expected decision in the first half of 2018. ACC also has accepted two poster presentations regarding the unmet medical need for anticoagulant prophylaxis of venous thromboembolism in acute medically ill patients.